According to a new study published in the journal Digestive Diseases, researchers have found that the duration of stability is linked with overall survival in patients with advanced hepatocellular carcinoma treated with the tyrosine kinase inhibitor sorafenib.
For the study, researchers identified 269 patients with advanced hepatocellular carcinoma who were treated with sorafenib at the Kinki University Hospital in Japan between May 2009 and January 2013.
Of those 269, 158 patients' antitumor response of sorafenib were analyzed and patients were either classified as having a short period of stable disease (<3 months) or a long period of stable disease (≥3 months).
Results showed patients classified as having short stable disease had a median overall survival of 5.7 months and patients in the long stable disease had a median overall survival of 20.8 months. Patients with a complete response or a partial response had a median overall survival of 17.9 months.
The results suggest an association between patients who have a long duration of stable disease and overall survival.
This study aimed to clarify the correlation between stable disease (SD) periods and overall survival (OS) in patients with hepatocellular carcinoma (HCC) treated with sorafenib. Achievement of long SD is one of the important goals for improving survival in patients with HCC treated with sorafenib.